Alterity Therapeutics (ATHE) announced that new presentations related to its Multiple System Atrophy program were delivered at the American ...

Multiple system atrophy (MSA) refers to a group of progressive neurodegenerative disorders that affects the basal ganglia and the motor system (parkinsonism), autonomic nervous system (dysautonomia ...

Clinical practices and diagnostic challenges increase misdiagnoses Commonly revised diagnoses include vascular parkinsonism, ...

As an iron chaperone, it has excellent potential to treat Parkinson’s disease as well as various Parkinsonian disorders such as Multiple System Atrophy (MSA). ATH434 successfully completed Phase ...

Opens in a new tab or window A machine learning model differentiated Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. AUROCs and predictive values for ...

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today ...

The ATH434-202 is an open label study designed to evaluate the safety, efficacy and target engagement of ATH434 in participants with advanced multiple system atrophy (MSA). “Following the ...

Steve Hyslop George Stephen “Steve” Hyslop, a loving husband, dedicated father, adoring grandfather, and pillar of Santa Barbara hospitality, passed away ...

Analyses from Randomized Controlled Trials Further Support the Target Engagement and Safety Profile of Ampreloxetine in Neurodegenerative Disease< ...

Nitrated α-synuclein is upregulated in the CSF of patients with Parkinson’s Disease (PD), Lewy body dementia (DLB), multiple system atrophy (MSA), and other synucleinopathies.